You just read:

Lilly announces publication of analyses showing benefit of the addition of Verzenio® (abemaciclib) in multiple subgroups of patients with advanced breast cancer identified as having a more concerning prognosis

News provided by

Eli Lilly and Company

Dec 18, 2018, 06:45 ET